38,244.04 DMD Permanently Burned in the Past 7 Days
On June 25, 2026, the latest on-chain data from DMDAO revealed that a total of 38,244.04 DMD has been permanently burned through the established transaction and wealth management burn mechanisms over the past 7 calendar days.
Approaching the Target Total Supply: As the burning continues, DMD is steadily converging toward its hard cap of 1,000,000 tokens. Driven by ongoing on-chain interactions and native system mechanisms, the overall circulating supply in the market is continuously shrinking.
Robust Business Performance: The steady accumulation of burned tokens directly reflects the underlying market-making system's recent high-frequency spread-capture capabilities and genuine on-chain activity. Powered by this deflationary model, the reduction in circulating supply effectively enhances the value-bearing capacity of existing tokens.
Optimistic Market Liquidity Outlook: With public market trading pairs running smoothly, DMD is progressively integrating into the broader secondary market. This not only attracts a diverse range of external participants to the project but also fosters long-term stability for the liquidity pool and expands the growth potential of the entire ecosystem.
The deflationary mechanism remains in active operation as the market structure continues to optimize. DMDAO will maintain full transparency by continuing to disclose data regularly.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%
Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.
Crypto prices
More
